Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication

被引:232
作者
Chun, Tae-Wook [1 ]
Justement, J. Shawn
Murray, Danielle
Hallahan, Claire W.
Maenza, Janine [2 ]
Collier, Ann C. [2 ]
Sheth, Prameet M. [3 ]
Kaul, Rupert [3 ]
Ostrowski, Mario [3 ]
Moir, Susan
Kovacs, Colin [3 ]
Fauci, Anthony S.
机构
[1] NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA
[2] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA
[3] Univ Toronto, Dept Med, Toronto, ON, Canada
基金
美国国家卫生研究院;
关键词
antiretroviral therapy; discontinuation of therapy; eradication; human immunodeficiency virus; viral reservoirs; EXTENDED PERIODS; PERSISTENCE; INFECTION; REPLICATION; SUPPRESSION; VIRUS;
D O I
10.1097/QAD.0b013e328340a239
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: Sustained suppression of plasma viremia in HIV-infected individuals is attainable with antiretroviral therapy (ART); however, eradication of virus that would allow discontinuation of ART has been hampered by the persistence of HIV reservoirs. It is of great interest to identify individuals who had received ART for prolonged periods of time with extremely low or undetectable HIV reservoirs and monitor plasma viremia following discontinuation of therapy. Methods: We measured the size of HIV reservoirs in CD4(+) T cells of individuals on long-term ART and monitored plasma viremia following cessation of ART in one individual with an exceptionally low viral burden after a decade of therapy. Results: We demonstrated undetectable levels of HIV DNA in the blood of eight of 45 infected individuals on long-term ART. Among those eight individuals, the frequency of cells carrying infectious virus was significantly lower in those who initiated ART during the early versus the chronic phase of infection. One individual with undetectable HIV DNA in both blood and tissue and a profoundly low level of infectious virus experienced plasma viral rebound 50 days following discontinuation of ART. Conclusions: Our data suggest that a significant reduction in the size of viral reservoirs may be achievable in selected individuals who initiate standard ART early in infection. However, given re-emergence of plasma viremia in an individual with an extraordinarily low viral burden, therapeutic strategies aimed at specifically targeting these extremely rare HIV-infected cells with novel interventions may be necessary in order to achieve eradication of virus. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:2803 / 2808
页数:6
相关论文
共 19 条
[1]   HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation [J].
Chomont, Nicolas ;
El-Far, Mohamed ;
Ancuta, Petronela ;
Trautmann, Lydie ;
Procopio, Francesco A. ;
Yassine-Diab, Bader ;
Boucher, Genevieve ;
Boulassel, Mohamed-Rachid ;
Ghattas, Georges ;
Brenchley, Jason M. ;
Schacker, Timothy W. ;
Hill, Brenna J. ;
Douek, Daniel C. ;
Routy, Jean-Pierre ;
Haddad, Elias K. ;
Sekaly, Rafick-Pierre .
NATURE MEDICINE, 2009, 15 (08) :893-U92
[2]   Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy [J].
Chun, Tae-Wook ;
Nickle, David C. ;
Justement, Jesse S. ;
Meyers, Jennifer H. ;
Roby, Gregg ;
Hallahan, Claire W. ;
Kottilil, Shyam ;
Moir, Susan ;
Mican, Joann M. ;
Mullins, James I. ;
Ward, Douglas J. ;
Kovacs, Joseph A. ;
Mannon, Peter J. ;
Fauci, Anthony S. .
JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (05) :714-720
[3]   Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus [J].
Chun, Tae-Wook ;
Justement, J. Shawn ;
Moir, Susan ;
Hallahan, Claire W. ;
Maenza, Janine ;
Mullins, James I. ;
Collier, Ann C. ;
Corey, Lawrence ;
Fauci, Anthony S. .
JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (12) :1762-1764
[4]   HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir [J].
Chun, TW ;
Nickle, DC ;
Justement, JS ;
Large, D ;
Semerjian, A ;
Curlin, ME ;
O'Shea, MA ;
Hallahan, CW ;
Daucher, M ;
Ward, DJ ;
Moir, S ;
Mullins, JI ;
Kovacs, C ;
Fauci, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3250-3255
[5]   AIDS - Re-emergence of HIV after stopping therapy [J].
Chun, TW ;
Davey, RT ;
Engel, D ;
Lane, HC ;
Fauci, AS .
NATURE, 1999, 401 (6756) :874-875
[6]   Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy [J].
Chun, TW ;
Stuyver, L ;
Mizell, SB ;
Ehler, LA ;
Mican, JAM ;
Baseler, M ;
Lloyd, AL ;
Nowak, MA ;
Fauci, AS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (24) :13193-13197
[7]   Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy [J].
Chun, TW ;
Engel, D ;
Mizell, SB ;
Hallahan, CW ;
Fischette, M ;
Park, S ;
Davey, RT ;
Dybul, M ;
Kovacs, JA ;
Metcalf, JA ;
Mican, JM ;
Berrey, MM ;
Corey, L ;
Lane, HC ;
Fauci, AS .
NATURE MEDICINE, 1999, 5 (06) :651-655
[8]   HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression [J].
Davey, RT ;
Bhat, N ;
Yoder, C ;
Chun, TW ;
Metcalf, JA ;
Dewar, R ;
Natarajan, V ;
Lempicki, RA ;
Adelsberger, JW ;
Millers, KD ;
Kovacs, JA ;
Polis, MA ;
Walker, RE ;
Falloon, L ;
Masur, H ;
Gee, D ;
Baseler, M ;
Dimitrov, DS ;
Fauci, AS ;
Lane, HC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) :15109-15114
[9]   Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy [J].
Finzi, D ;
Hermankova, M ;
Pierson, T ;
Carruth, LM ;
Buck, C ;
Chaisson, RE ;
Quinn, TC ;
Chadwick, K ;
Margolick, J ;
Brookmeyer, R ;
Gallant, J ;
Markowitz, M ;
Ho, DD ;
Richman, DD ;
Siliciano, RF .
SCIENCE, 1997, 278 (5341) :1295-1300
[10]   Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy [J].
Kulkosky, J ;
Nunnari, G ;
Otero, M ;
Calarota, S ;
Dornadula, G ;
Zhang, H ;
Malin, A ;
Sullivan, J ;
Xu, Y ;
DeSimone, J ;
Babinchak, T ;
Stern, J ;
Cavert, W ;
Haase, A ;
Pomerantz, RJ .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10) :1403-1411